Page last updated: 2024-10-30

leflunomide and Sclerosis, Systemic

leflunomide has been researched along with Sclerosis, Systemic in 4 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
"Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide."7.88Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018)
"Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide."3.88Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, SY1
Lee, SW1
Chung, WT1
Oliveira, AC1
Mota, LM1
Santos-Neto, LL1
Simões, M1
Martins-Filho, OA1
Tauil, PL1
Gordeev, AV1
Mutovina, ZIu1
Nasankaeva, EK1
Sebastiani, M1
Giuggioli, D1
Vesprini, E1
Caruso, A1
Ferri, C1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area[NCT03430388]600 participants (Actual)Interventional2018-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

4 other studies available for leflunomide and Sclerosis, Systemic

ArticleYear
Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report.
    Medicine, 2018, Volume: 97, Issue:47

    Topics: Arthritis, Rheumatoid; Calcinosis; Female; Humans; Immunosuppressive Agents; Leflunomide; Middle Age

2018
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
    Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumat

2015
[Effective treatment of systemic sclerosis with leflunomide].
    Terapevticheskii arkhiv, 2005, Volume: 77, Issue:5

    Topics: Aged; Female; Humans; Isoxazoles; Leflunomide; Scleroderma, Systemic; Treatment Outcome

2005
Successful treatment with leflunomide of arthritis in systemic sclerosis patients.
    Rheumatology (Oxford, England), 2006, Volume: 45, Issue:9

    Topics: Adult; Antirheumatic Agents; Arthritis; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; Sclero

2006